Cassidy Bio Ltd.

Cassidy Bio Ltd. , based in Tel Aviv-Yafo, Israel, specializes in AI-driven genome editing design, focusing on enhancing the safety and scalability of gene editing therapies through advanced computational intelligence and extensive genomic datasets. Founded in 2024, Cassidy Bio Ltd. operates as an independent entity in the biotechnology sector, focusing on AI-powered genomic solutions.

n November 2025, Cassidy Bio Ltd. raised USD 8 million in seed funding led by Ahren Innovation Capital, with participation from lool ventures, 10D and AION Labs. The headquarters is located in Tel Aviv-Yafo, Israel. Cassidy Bio specializes in AI-powered genome editing design, developing safer and more scalable gene editing therapies.

Their proprietary genomic foundation model streamlines the gene editing process, utilizing a database of 70,000 genetically diverse human genomes to enhance safety and efficacy. They provide solutions tailored to biotechnology firms, research institutions, and healthcare providers focused on genetic therapies across North America, Europe, and select regions in Asia. Cassidy Bio generates revenue through partnerships and collaborations with biotech companies and research institutions leveraging its AI-driven genomic solutions. The B2B model allows clients to access the platform for gene editing design via fee-for-service agreements or subscriptions, supporting various applications including personalized CRISPR therapies, with flagship offerings like CASGEVY™ for sickle-cell disease and beta-thalassemia.

In November 2025, Cassidy Bio Ltd. raised USD 8. 00 mn in Seed funding to expand its AI platform for gene editing, with plans to enhance simulations and conduct laboratory validations. The funding will support the development of new products aimed at improving gene editing capabilities, while the company targets expansion into additional markets across Europe and Asia by 2026.